Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Misses on Revenue, Stock Down 0.97%

Aurinia Pharmaceuticals reported a narrower-than-expected loss per share, but did not provide revenue figures. The stock reacted with a slight decline of 0.97%, indicating that investors may have been looking for more clarity or positive news in other areas. The lack of guidance and commentary from management may have contributed to the stock's downward movement.